Motexafin Lutetium

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameMotexafin Lutetium
Drug Alias NameLutetium texaphyrin莫特沙芬镥OptrinLutrinAntrin +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhotosensitizers
TargetsNot applicable
Therapy Area/IndicationsAtherosclerosisProstatic NeoplasmsUterine Cervical Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPharmacyclics Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPharmacyclics LlcNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsAtherosclerosisProstatic NeoplasmsUterine Cervical Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG